HIF1A and neoplasm: One recent study has shown that mice immunized by a HIF-1α peptide pool, namely the HIF-1α vaccine, have a higher level of HIF-1-specific IgG in sera, which neutralizes HIF-1α, enhances Th1 and Th2 immunity, and reduces tumor growth in TNBC and activities of BCSCs [214].